Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...

"Overall, metabolic responses to glucagon stimulation in individuals with type 1 diabetes are comparable to those in healthy ...

CHICAGO and ARLINGTON, Va. - The American Diabetes Association and a national supporter, Xeris Pharmaceuticals, have formed a multi-year strategic partnership to reinforce the importance of prescribin ...

Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Israeli and American researchers uncovered the role of a specific enzyme in managing blood sugar levels in a study that opens up new therapeutic possibilities for people with type 2 diabetes. Type 2 ...

Findings suggest targeting neuro-immune pathway could lead to strategies for managing diabetes, obesity or some types of ...

Glucagon prescriptions for severe hypoglycemia rose in Medicaid beneficiaries with the introduction of newer products but likely met only a fraction of the high-risk population’s needs.

During the seventeen years that have followed this discovery many new compounds that have had in common the ability to cause hypoglycemia have been investigated both clinically and in the laboratory.

These data support our hypotheses that the glucagon response to hypoglycemia is reduced in patients who are approaching the insulin-deficient end of the spectrum of type 2 diabetes and that recent ...